ESH ALL 2021 | Prognostic relevance of monocytic switch and future research
Ester Mejstříková, PhD, and Michaela Nováková, PhD, Second Faculty of Medicine, Charles University, Prague, Czech Republic, comment on the prognostic relevance of the monocytic switch. A study describing the molecular landscape of acute lymphoblastic leukemia (ALL) with monocytic switch indicates that the prognosis of patients with monocytic switch is comparable with those without. Dr Mejstříková highlights the impact of the switching phenomenon on relapse risk. Currently, the malignant potential of the switched monocytic blasts remains unknown. Future research looking at the expression profile and MRD assessment improvement will help expand our knowledge about this rare phenomenon. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Dr Mejstříková’s lab was involved in MRD assessment for Amgen
